Friday, 04 December 2020

Ricovr inks partnership with IIT-M for PoC testing

23 December 2019 | News

To Bolster Point-of-Care Medical Device Development

image credit-

image credit-

Ricovr Inc., a New Jersey based innovative oral diagnostics medical device company, has announced its partnership with renowned engineering organization, the Indian Institute of Technology Madras (IIT-M), India.

Ricovr is currently working on building a cutting-edge medical device for point-of-care (PoC) testing using saliva. This collaboration with IIT Madras will help Ricovr advance its Research and Development efforts by bringing together some of the most talented and experienced professionals in the biosensor industry.

Ricovr is in the midst of creating a revolutionary product that uses patent-pending nanoscale technology. Their products will benefit businesses, law enforcement officials, and the medical community by providing timely screening and monitoring.

Highlighting the impact of this collaboration, Dr. Himanshu Bhatia, Founder and Chief Executive Officer, Ricovr Inc., said, “Ricovr is on its way to being one of the top medical device innovators. Our collaborative efforts with IIT Madras position us to be able to deliver world-class scientific advancements in an exciting emerging space. This partnership will help us attain our goal of developing and commercializing point-of-care medical devices for diverse markets.”

This collaboration is taking place during a time of tremendous momentum for Ricovr, which recently expanded its senior leadership team. Ricovr plans to release additional details about its point-of-care diagnostics device in coming months.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls